![]() ![]() Immuno-oncology is a relatively new therapeutic area that tries to develop treatments to enhance the body’s immune system to fight cancer. Most new products fail between the preclinical or clinical trial phases – more so in oncology (the study and diagnosis of tumours) than other areas of medicine. The time taken from exploring preclinical science to a treatment used in practice can be up to 17 years. If a drug or other treatment is proven to work, it then has to be approved by the drugs regulators, such as the US Food and Drug Administration or the European Medicines Agency. Preclinical studies are followed by testing in humans – clinical trials – which can take many years. The hope is that the findings from this stage of research will eventually “translate” into new or better treatments for cancer. Pre-clinical studies are the earliest stage of research. In terms of the type of research, preclinical research (typically laboratory studies) received US$18 billion (73.5%). We found that the cancer types receiving the most funding were breast (US$2.73 billion, 11.2% of the total) and haematological cancer (typically referring to leukaemia, US$2.3 billion, 9.4%). This is important as it allows us to understand who is funding what in cancer research and to understand whether research gaps may exist. ![]() Our analysis compares the level of funding given to researching different types of cancers with the health burden of those types of cancer. This makes it difficult to look into how the money was spent in detail. They rely on top-level summaries in annual reports and other infographics, which is insufficient for analyses such as ours. This allows for scrutiny around their portfolios and allows those who set funding priorities to better understand how to allocate limited resources for health research.Īmong the major global health funders, Cancer Research UK is one of the few that does not provide data on funding at the individual award level. Most of the world’s biggest funders are transparent about their funding decisions, providing data on their grants. This amounted to US$24.5 billion (£19.7 billion) of investment across 66,388 research grants.īy country, the US provided 57.3% of the total cancer research funding awarded, with the US National Institute of Health being by far the biggest funder. To get a clearer picture of where cancer research funding is spent, we collected and compiled data covering public and charitable cancer research investments, globally, between 20, inclusive. Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.Ĭancer research is vital to helping ease this global burden, but where and how research money is spent doesn’t always match with where and how help is needed. By 2040, that number is expected to reach 28 million. In 2020, 19 million people around the world received a cancer diagnosis. University of Southampton provides funding as a member of The Conversation UK. Queen's University Belfast provides funding as a founding partner of The Conversation UK. He has received institutional payments for advisory boards and speaker bureaux from MSD, Lilly, Roche, Astra Zeneca and BD Medical, and travel and conference support from Roche, MSD and Lilly. Stuart McIntosh receives grant funding from the National Insititute of Health Research and Cancer Research UK. ![]() Ramsey Cutress receives grant funding from the NIHR, Prevent breast cancer, World Cancer Research Fund, Association of Breast Surgery, Astra Zeneca and institutional research support from seca. Michael Head has previously received funding from the Bill & Melinda Gates Foundation and the UK Department for International Development. ![]() Professor, Breast Surgery, University of SouthamptonĬlinical Reader in Surgical Oncology, Queen's University Belfast Senior Research Fellow in Global Health, University of Southampton ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |